Expression plasmids are only useful for the investigation of co-receptor tropism and fusion capacity of short HIV-1 envelope domains

Journal of Virological Methods

Volumn 166, Issue 1-2, 2010, Pages 106-109

  Grund, S ^a   Klein, A ^a   Adams, O ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Co receptor tropism analysis; Expression plasmids; Fusion capacity; HIV 1; Primary isolates

Indexed keywords

GLYCOPROTEIN GP 41; PROTEIN NL4 3; PROTEIN V3; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CD4+ T LYMPHOCYTE; CHIMERA; EXPRESSION VECTOR; GENE CONSTRUCT; GENE FUSION; GENE INSERTION; HELA CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRION; VIRUS CELL INTERACTION; VIRUS ISOLATION; VIRUS STRAIN; WILD TYPE;

ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HELA CELLS; HIV-1; HUMANS; PLASMIDS; PROTEIN BINDING; RECEPTORS, HIV; VIRAL TROPISM; VIROLOGY; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77952673177     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.03.015     Document Type: Article

References (25)

1. Abacioglu H., Okuyan M. Antibody to the human immunodeficiency virus in a commercial gammaglobulin preparation. J. Infect. Dis. 1989, 160:161-162.
2. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59:284-291.
3. Adams O., Schaal H., Scheid A. Natural variation in the amino acid sequence around the HIV type 1 glycoprotein 160 cleavage site and its effect on cleavability, subunit association, and membrane fusion. AIDS Res. Hum. Retroviruses 2000, 16:1235-1245.
4. Ait-Khaled M., Emery V.C. Sequence variation within the human immunodeficiency virus V3 loop at seroconversion. J. Med. Virol. 1993, 41:270-274.
5. Bosch V., Pawlita M. Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site. J. Virol. 1990, 64:2337-2344.
6. Cao J., Bergeron L., Helseth E., Thali M., Repke H., Sodroski J. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 1993, 67:2747-2755.
7. Chang D.K., Chien W.J., Cheng S.F. The FLG motif in the N-terminal region of glucoprotein 41 of human immunodeficiency virus type 1 adopts a type-I beta turn in aqueous solution and serves as the initiation site for helix formation. Eur. J. Biochem. 1997, 247:896-905.
8. Chesebro B., Wehrly K., Nishio J., Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J. Virol. 1992, 66:6547-6554.
9. Chesebro B., Wehrly K., Nishio J., Perryman S. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J. Virol. 1996, 70:9055-9059.
10. De Jong J.J., Goudsmit J., Keulen W., Klaver B., Krone W., Tersmette M., De R.A. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J. Virol. 1992, 66:757-765.
11. Fouchier R.A., Brouwer M., Broersen S.M., Schuitemaker H. Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J. Clin. Microbiol. 1995, 33:906-911.
12. Freed E.O., Myers D.J., Risser R. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:4650-4654.
13. Guo H.G., Veronese F.M., Tschachler E., Pal R., Kalyanaraman V.S., Gallo R.C., Reitz M.S. Characterization of an HIV-1 point mutant blocked in envelope glycoprotein cleavage. Virology 1990, 174:217-224.
14. Hamer D.H., Leder P. Splicing and the formation of stable RNA. Cell 1979, 18:1299-1302.
15. Hoffman N.G., Seillier-Moiseiwitsch F., Ahn J., Walker J.M., Swanstrom R. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J. Virol. 2002, 76:3852-3864.
16. Ivanoff L.A., Looney D.J., McDanal C., Morris J.F., Wong-Staal F., Langlois A.J., Petteway S.R., Matthews T.J. Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain. AIDS Res. Hum. Retroviruses 1991, 7:595-603.
17. Kabat D., Kozak S.L., Wehrly K., Chesebro B. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J. Virol. 1994, 68:2570-2577.
18. Moore J.P., McKeating J.A., Huang Y.X., Ashkenazi A., Ho D.D. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 1992, 66:235-243.
19. Owens R.J., Tanner C.C., Mulligan M.J., Srinivas R.V., Compans R.W. Oligopeptide inhibitors of HIV-induced syncytium formation. AIDS Res. Hum. Retroviruses 1990, 6:1289-1296.
20. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminating inhibitors, 1977. Biotechnology 1992, 24:104-108.
21. Srivastava K.K., Fernandez-Larsson R., Zinkus D.M., Robinson H.L. Human immunodeficiency virus type 1 NL4-3 replication in four T-cell lines: rate and efficiency of entry, a major determinant of permissiveness. J. Virol. 1991, 65:3900-3902.
22. Stamatatos L., Cheng-Mayer C. Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability. J. Virol. 1993, 67:5635-5639.
23. Tersmette M., Gruters R.A., de W.F., de Goede R.E., Lange J.M., Schellekens P.T., Goudsmit J., Huisman H.G., Miedema F. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J. Virol. 1989, 63:2118-2125.
24. Wahlberg J., Albert J., Lundeberg J., Von G.A., Broliden K., Utter G., Fenyo E.M., Uhlen M. Analysis of the V3 loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid-phase DNA sequencing. AIDS Res. Hum. Retroviruses 1991, 7:983-990.
25. Whitcomb J.M., Huang W., Fransen S., Limoli K., Toma J., Wrin T., Chappey C., Kiss L.D., Paxinos E.E., Petropoulos C.J. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 2007, 51:566-575.